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tumor necrosis factor-a (TNF-a) in rat L6 cells. TNF-a downregulated insulin-stimulated glucose
uptake and increased Serine 307 phosphorylation of insulin receptor substrate-1 (IRS-1). However,
the treatment of ALC improved insulin-stimulated glucose uptake via AMP-activated protein kinase
(AMPK) activation in a dose-dependent manner. Together, our data suggest that ALC inhibits TNF-a-
induced insulin resistance through AMPK pathway in skeletal muscle cells.
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Insulin resistance is deﬁned as the reduced ability of cells or tis-
sues to respond to physiological levels of insulin and is a character-
istic condition of most patients with type 2 diabetes mellitus
(T2DM). Studies in human insulin resistance have revealed a clear
association between the chronic activation of pro-inﬂammatory
signaling pathways and decreased insulin sensitivity. Expression
of tumor necrosis factor a (TNF-a) was markedly increased in
adipose tissue and muscle of insulin-resistant human and animals
[1–3].
Skeletal muscle is recognized as the major tissue of insulin-
stimulated glucose disposal. Because isolation of skeletal muscle
requires intact excision to preserve membrane integrity and the
tissue preparation has relatively short survival in vitro, appropriate
cell lines are vital to research. Rat L6 myoblast cells, derived from
the rat skeletal muscle cell lines, express the morphological, bio-
chemical and metabolic properties of isolated skeletal muscle
including insulin responsiveness. L6 cells and rat skeletal muscle
cells have been shown to have similar sensitivities to the harmfulchemical Societies. Published by E
P-activated protein kinase;
r 4; IRS-1, insulin receptor
itol-3 kinase; T2DM, type 2
ang), liyongbmu@163.comeffects of inﬂammatory cytokines including TNF-a. Hence, L6 cells
are used as a tool in exploring the mechanisms involved in the
pathogenesis of diabetes.
L-Carnitine (LC) is a small, water-soluble molecule important for
fat metabolism and for the normal function of energy metabolism
in most tissues. LC deﬁciency causes a defect in energy metabolism
and decreases energy production. Acetyl-L-carnitine (ALC) is the
acetyl ester of LC and is naturally occurring quaternary ammonium
compound, which is endogenously synthesized in human or ob-
tained from dietary sources [4]. Diabetic patients have been indi-
cated to be deﬁcit in ALC, and this deﬁciency involves in the
pathogenesis of diabetes [5]. In preclinical study, recruiting the
ALC for diabetic animal corrects perturbations of myoinositol, ni-
tric oxide, prostaglandins, and lipid peroxidation, all of which are
important for the early pathogenesis of diabetes [6,7]. In addition,
clinical studies have shown that ALC is effective for treating dia-
betic painful neuropathies [8,9].
However the effects of ALC on cytokine-induced insulin resis-
tance are not known. Thus, the aim of this study was to investigate
the effect of ALC on TNF-a induced insulin resistance in rat L6 cells.2. Materials and methods
2.1. Reagents
The rat L6 myoblast cell line was obtained from the ATCC
(American Types Culture Collection, USA). High glucose-DMEMlsevier B.V. All rights reserved.
Fig. 1. ALC increases insulin stimulated glucose uptake in TNF-a treated L6 cells. L6
cells were incubated for 24 h with either ALC or TNF-a (10 ng/ml) or insulin
(100 nM) and then assay for 2-deoxyglucose uptake, as described in Section 2. Each
value is expressed as means ± S.D. of three determinations. *P < 0.05, as compared
with insulin control group, #P < 0.05, as compared with TNF-a group.
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2-deoxyglucose, cytochalasin B were purchased from Sigma. TNF-a
was from Peprotech. insulin receptor substrate-1 (IRS-1), phospho-
IRS-1(Ser307), AMP-activated protein kinase (AMPK), phospho-
AMPK(Thr172), Akt and phospho-Akt(Ser473) antibodies were from
Millipore. b-actin, secondary HRP linked antibodies and ECL were
from Cell Signal Technology. Wortmannin were from Invitrogen
and compound C was from Merck.
2.2. Cell culture
The L6 cells were maintained in high glucose-DMEM supple-
mented with 10% FBS, 2 mM L-glutamine, and kept at 37 C in a
humidiﬁed atmosphere of 5% CO2 in air. For differentiation, the
cells were seeded in appropriate culture plates, and after sub-con-
ﬂuence (about 70%), the medium was changed to DMEM supple-
mented with 2% FBS. The medium was then changed every 2
days until the cells were fully differentiated. Cells were treated
in the absence or presence of TNF-a (10 ng/ml) over a time course
of 24 h. In set of experiments, cells were pretreated with different
dose of ALC for 3 h prior to TNF-a stimulation.
2.3. 2-Deoxyglucose uptake assay
The assay was initiated via the addition of [3H]-2-deoxyglucose
(25 mM; 10 mCi/ml) to each of the wells for 10 min at 37 C. The
assay was terminated via the addition and subsequent washing
of the cells with ice-cold PBS. The cells were lysed in 10% SDS or
50 mM NaOH. Radioactivity was evaluated via scintillation count-
ing of the lysates extracted in SDS, whereas total protein contents
were determined in lysates extracted in NaOH via the Bradford
procedure (Bio-Rad Laboratory, Richmond, CA, USA). The glucose
uptake values were corrected for non-carrier-mediated transport
by measuring glucose uptake in the presence of 10 mM cytochala-
sin B.
2.4. Immunoblot analysis
At the end of the experiments, cells were collected and stored at
80 C until further analysis. The cells were rinsed with PBS and
collected in a total volume of 200 lL of homogenizing buffer.
Immediately after collection, the cells were sonicated for 5 s prior
to storage. Protein assays were conducted and 20 lg of protein
were used for immunoblotting. The blots were then visualized
via ECL.
2.5. Data analysis
Data were expressed as means ± S.D. Statistic analysis for
multiple comparisons was conducted with one-way analysis of
variance (ANOVA). P values <0.05 were considered statistically
signiﬁcant.Fig. 2. Effect of ALC on IRS-1 phosphorylation in TNF-a treated L6 cells via western
blotting for anti phospho-IRS-1 (Ser307) antibody. Blotting with anti IRS-1 and b-
actin antibodies was conducted as a protein loading control. *P < 0.05, as compared
with insulin control group, #P < 0.05, as compared with TNF-a group. Immunoblot
ﬁgures are representative of three independent experiments and each value is
expressed as means ± S.D.3. Results
3.1. ALC increases insulin-induced glucose uptake in TNF-a treated L6
cells
In our study, L6 cells were treated with TNF-a (10 ng/ml, 24 h)
to induce insulin resistance. Insulin-induced glucose uptake was
measured to determine insulin sensitivity. Our results showed that
insulin-induced glucose uptake was 2.3 times higher than that in
normal control group (Fig. 1). Contrary to the insulin-stimulated
control group, the TNF-a treatment inhibited insulin-stimulated
glucose uptake by over 67% and TNF-a alone inhibited glucoseuptake by 20% compared to normal control group. However, pre-
treated for 3 h with ALC prior to TNF-a stimulation reversed the
condition completely in a dose-dependent manner. Insulin-in-
duced glucose uptake was increased by 60% and 110% after inter-
vention with 0.6 and 1.2 mM ALC.
3.2. ALC inhibits TNF-a-induced IRS-1 Ser307 phosphorylation in L6
cells
When IRS-1 is alternatively phosphorylated on serine 307, its
downstream signaling ability is diminished. Since phosphorylation
precedes IRS-1 degradation and ser307 phosphorylation of IRS-1
has become a molecular indicator of insulin resistance, we investi-
gated the effect of ALC on IRS-1 Ser307 phosphorylation with phos-
pho-Ser307 IRS-1 antibody by immunoblotting in TNF-a treated L6
cells. We found that TNF-a may have induced IRS-1 Ser307 phos-
phorylation and ALC (0.6 and 1.2 mM) were found to reduce IRS-
1 Ser307 phosphorylation in a dose-dependent manner (Fig. 2).
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To ﬁnd the factor mediating IRS-1 phosphorylation, we exam-
ined the phosphorylation of AMPK by cotreated ALC and TNF-a
in L6 cells. L6 cells already have a basal level of phosphorylated
AMPK under excessive TNF-a condition; however, these levels in-
creased by coincubated with ALC in a dose-dependent manner
(Fig. 3A). Interestingly, the addition of compound C, an AMPK spe-
ciﬁc inhibitor, could diminish the ALC induced IRS-1 Ser307 phos-
phorylation inhibition (Fig. 3B). As the observations, it has raised
the possibility that ALC increased insulin sensitivity in TNF-a trea-
ted L6 cells might be the consequence depending on AMPK
activation.
3.4. Effect of ALC on insulin induced Akt phosphorylation under TNF-a
condition
To test the involvement of insulin-stimulated Akt, the cellular
content of Akt (Ser473) phosphorylation proteins was evaluated in
total cell lysates by western blot. The treatment of cells with
TNF-a clearly blocked the insulin induced Ser473 phosphorylation
of Akt. The inhibition of Akt Ser473 phosphorylation can be reversed
by treatment with ALC in a dose-dependent manner (Fig. 4A).
Notably, we also observed that wortmannin, a PI3K speciﬁc inhib-
itor didn’t inhibited the ALC-induced phosphorylation of Akt, sug-Fig. 3. ALC stimulates AMPK pathway in TNF-a treated L6 cells. (A) Dose-
dependent phosphorylation of AMPK by ALC. L6 cells were cultured for 24 h in
the presence of 10 ng/ml TNF-a and in different doses of ALC as indicated in the
ﬁgure. The cell lysates were analyzed via Western blotting for anti phospho-AMPK
(Thr172) antibody. Blotting with anti-AMPK antibody was conducted as a protein
loading control. *P < 0.05 compared to insulin control group. #P < 0.05 compared to
TNF-a alone group. (B) L6 cells were incubated with 10 ng/ml TNF-a and 0.6mM
ALC for 24 h in the presence or absence of compound C (10 lM). The cell lysates
were analyzed via western blotting for anti phospho-IRS-1(Ser473) antibody.
Blotting with anti IRS-1 antibody was conducted as a protein loading control.
Figures are representative of four independent experiments. *P < 0.05 compared to
TNF-a alone group. #P < 0.05 compared to ALC group.
Fig. 4. Effect of ALC on insulin induced Akt phosphorylation. (A) Dose-dependent
phosphorylation of Akt by ALC. L6 cells were cultured for 24 h in the presence of
10 ng/ml TNF-a and in different doses of ALC as indicated in the ﬁgure. The cell
lysates were analyzed via Western blotting for anti phospho-Akt (Ser473) antibody.
Blotting with anti-Akt antibody was conducted as a protein loading control.
*P < 0.05 compared to insulin control group. #P < 0.05 compared to TNF-a alone
group. (B) L6 cells were pretreated with wortmannin (100 nM) for 30 min and then
stimulated with 10 ng/ml TNF-a and 0.6 mM ALC for 24 h. The cell lysates were
analyzed via western blotting for anti phospho-Akt (Ser473) antibody. Blotting with
anti Akt antibody was conducted as a protein loading control. The blots are
representative of four repeated blots. *P < 0.05 compared to TNF-a alone group.gesting that the ALC action may not go through upstream of PI3K-
Akt signaling pathway (Fig. 4B).
4. Discussion
Skeletal muscle accounts for approximately 75% of glucose
absorption under insulin-stimulated conditions [10] and a reduc-
tion in insulin-stimulated glucose uptake in skeletal muscles of
type 2 diabetic patients has been observed both in vitro [11] and
in vivo [12]. Skeletal muscle is considered an important therapeu-
tic target tissue for T2DM [13]. The potential effect of ALC on insu-
lin-stimulated glucose uptake in cultured rat L6 cells exposed to
TNF-a was investigated in the present study. Our results validated
the enhancement on insulin-stimulated glucose uptake in TNF-a
treated L6 cells by ALC which was consistent with its action of low-
ering blood glucose level in animal and clinical trials [14,15].
It has been established that increasing muscle total carnitine
content in healthy human reduces muscle glycolysis, increases gly-
cogen storage and is accompanied by an apparent increase in fat
oxidation [16]. Previous data have conﬁrmed that free and acety-
lated forms of L-carnitine can increase glucose disposal in type 2
diabetic patients [14,17]. A crucial question herein remains as to
how ALC can ameliorate the TNF-a-induced insulin resistance.
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tance because it is elevated in the circulation, skeletal muscle
and adipose tissue of patients with type 2 diabetes. Although the
mechanisms by which TNF-a causes insulin resistance are un-
known, a possible explanation for the inhibitory effect of TNF-a
on insulin action is that it triggers an alternation in cellular signal-
ing pathway due to prolonged exposure. TNF-a can function as sig-
naling molecules to activate a number of stress sensitive serine/
threonine kinase pathways linked to insulin resistance [18]. A re-
cent study has demonstrated that TNF-a can induce skeletal mus-
cle insulin resistance via suppressing AMPK signaling [19]. AMPK is
pivotal in the regulation of skeletal muscle fatty-acid metabolism.
AMPK activation results in increasing rates of skeletal muscle fatty-
acid oxidation by phosphorylating acetyl-CoA carboxylase (ACC),
leading to reduced malonyl-CoA and increased long-chain fatty
acyl CoA ﬂux into the mitochondria via carnitine palmitoyl trans-
ferase-1 [20].
The insulin signaling pathways offer a number of potential sub-
strates for these activated serine kinases including the insulin
receptor and the family of IRS proteins. Increased serine phosphor-
ylation of IRS-1 decreases the extent of insulin stimulated tyrosine
phosphorylation and attenuates insulin action which has been
identiﬁed insulin resistance in vitro and in vivo. In this study, we
demonstrated that the exposure to TNF-a for 24 h resulted in
Ser307 phosphorylation of IRS-1 which was consistent with the pre-
vious study [21]. This provided the indication that increasing Ser307
IRS-1 phosphorylation could affect insulin action. Moreover, we
also displayed that the ALC treatments signiﬁcantly reversed these
TNF-a effects. These effects of ALC were all dose-dependent which
was likely through upregulation of IRS-1 activity. Here, our data
provided a new molecular mechanism how the ALC can alleviate
insulin resistance under TNF-a condition.
At the cellular level, insulin signaling involves a complex signal-
ing cascade downstream of the insulin receptor [22]. AMPK path-
way is also a major regulator of glucose transporter 4 (GLUT4)
translocation during exercise or in response to some antidiabetic
agents such metformin [23]. In our work, ALC could increase the
phosphorylation of AMPK compared to TNF-a treatment, suggest-
ing that the AMPK signaling pathway is likely responsible for the
stimulation of glucose uptake by ALC. In addition, we investigated
whether the IRS-1 Ser307 phosphorylation inhibition was related to
AMPK phosphorylation. An interesting ﬁnding was that AMPK
mediated the ALC inhibition of IRS-1 serine phosphorylation. In
this study we have conﬁrmed that ALC was indeed inhibitory to
Ser307 phosphorylation in IRS-1. However, this effect could be abol-
ished by the AMPK inhibitor compound C. Our results showed that
ALC insulin-enhancing effects in TNF-a treated L6 cells were re-
quired for the activation of AMPK and the consequent inhibition
of IRS-1 serine phosphorylation.
To be further, we also demonstrated that ALC exhibited an
enhancement on insulin-mediated Akt phosphorylation, however,
which was not inhibited by wortmannin, an inhibitor of PI3K. In-
deed, our results indicated that ALC did not alone affect Akt phos-
phorylation signiﬁcantly, but augment insulin signaling pathway
by activating AMPK, which eventually led to Akt activation [24].
Reports concerning interactions between PI-3K/Akt and AMPK
are controversial. First, AMPK has been reported to stimulate
GLUT4 translocation independently of PI-3k/Akt. However, it was
also proposed that AMPK has potential role in regulation of insulin
action, thus increasing the complexity of understanding the inter-
connection of these two signaling pathways. Taken together, the
interaction between these two signaling pathways can be partly
explained by the differences in the experimental design and in con-
centration of reagents used. Further studies are required to eluci-
date the precise mechanisms interconnecting these two signaling
pathway.It has been well documented that both free and acetylated
forms of L-carnitine are taken up by cells via OCTN2, a Na+-depen-
dent organic cation transporter [25]. Since the efﬁcacy of OCTN2
for the transport of acetyl-L-carnitine is higher than that for L-car-
nitine [26], the difference in their ability to accumulate in L6 cells
might reﬂect the difference in the prohibitive effects of the two
compounds. Acetyl-L-catnitine enhances mitochondrial metabo-
lism via the catnitine/acetylcarnitine-mediated transfer of the
acetyl group that plays an important role in signal transduction
pathways and gene expression in muscle cells. Therefore acetyl-
L-cartinine is a form of L-carnitine which some scientists believe
is more bioavailable.
In summary, using L6 cells, we investigated how TNF-a prefer-
entially impaired insulin downsignaling and what the role ALC
played to alleviate this insulin resistance state. Our works found
that ALC inhibited TNF-a induced insulin resistance via activating
AMPK signaling, thus increasing rates of skeletal muscle fatty-acid
oxidation, leading to reduced malonyl-CoA and increased long-
chain fatty acyl CoA ﬂux into the mitochondria. Further experi-
ments directed at the determining the mechanism of ALC may lead
to the identiﬁcation of molecular targets for the generation of ther-
apeutic agents useful in the management of insulin resistance dis-
ease like diabetes.Acknowledgement
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